5-iodotubercidin has been researched along with harmine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baaten, J; Bursulaya, B; Colman, K; Deaton, L; DiDonato, M; Ding, Q; Espinola, S; Glynne, R; Gordon, WP; Ha, S; Hao, X; Harb, G; Hill, R; Jacobsen, K; Jia, Y; Jin, Q; Kamireddy, A; Laffitte, B; Lam, T; Li, J; Liu, B; Liu, YA; Loren, J; McNamara, P; Meeusen, S; Mo, T; Molteni, V; Nguyen, B; Nguyen-Tran, V; Pan, J; Pan, S; Petrassi, HM; Qiu, M; Schumacher, AM; Shen, W; Wang, Z; Wu, TY; Yan, S; Zhang, X; Zhang, YQ; Zou, Y | 1 |
1 other study(ies) available for 5-iodotubercidin and harmine
| Article | Year |
|---|---|
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.
Topics: Animals; Aza Compounds; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Type 1; Dyrk Kinases; Humans; Hypoglycemic Agents; Indoles; Insulin Secretion; Insulin-Secreting Cells; Male; Mice; Molecular Docking Simulation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2020 |